Valuation: Strides Pharma Science Limited

Market Cap 88.26B 923M 792M 740M 679M 1.28B 1.3B 8.73B 3.42B 44.26B 3.47B 3.39B 146B P/E 2027 *
14.1x
P/E 2028 * 10x
Enterprise Value 88.26B 923M 792M 740M 679M 1.28B 1.3B 8.73B 3.42B 44.26B 3.47B 3.39B 146B EV / Sales 2027 *
1.52x
EV / Sales 2028 * 1.28x
Free-Float
68.12%
Yield 2027 *
0.31%
Yield 2028 * 0.31%
1 day+1.21%
1 week-3.75%
Current month-6.47%
1 month-11.22%
3 months-17.05%
6 months+10.12%
Current year+6.06%
1 week 931.25
Extreme 931.25
997.6
1 month 931.25
Extreme 931.25
1,093.8
Current year 769.6
Extreme 769.6
1,231.45
1 year 769.6
Extreme 769.6
1,231.45
3 years 414.85
Extreme 414.85
1,675.25
5 years 263.45
Extreme 263.45
1,675.25
10 years 263.45
Extreme 263.45
1,675.25
Manager TitleAgeSince
Chief Executive Officer - 01/06/2024
Director of Finance/CFO 42 01/06/2024
Chief Tech/Sci/R&D Officer - 21/11/2024
Director TitleAgeSince
Chairman 65 -
Director/Board Member 82 18/05/2017
Director/Board Member 58 11/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.21%-3.75% - - 913M
+1.33%-2.26%+16.81%+67.42% 46.96B
+3.15%+0.04%+54.09%+130.29% 39.63B
-0.64%-2.80%-8.19%+15.01% 12.07B
-0.99%-8.34%+11.63%+70.49% 11.61B
0.00%+0.19%+30.00%+147.62% 9.11B
-0.39%-1.15%+19.93%+39.54% 7.47B
+0.83%+2.63%+46.24%-10.74% 7.18B
-2.54%-1.90%+15.45%+193.20% 6.79B
-3.28%-4.68%-33.43%+20.83% 5.75B
Average -0.13%-2.31%+16.95%+74.85% 16.29B
Weighted average by Cap. +0.93%-3.08%+24.81%+84.08%

Financials

2027 *2028 *
Net sales 58.23B 609M 523M 488M 448M 842M 856M 5.76B 2.25B 29.2B 2.29B 2.24B 96.56B 69.12B 723M 620M 579M 531M 999M 1.02B 6.84B 2.68B 34.67B 2.72B 2.66B 115B
Net income 6.28B 65.68M 56.34M 52.61M 48.26M 90.76M 92.25M 621M 243M 3.15B 247M 241M 10.41B 8.8B 92.05M 78.96M 73.73M 67.64M 127M 129M 870M 341M 4.41B 346M 338M 14.59B
Net Debt - -
Logo Strides Pharma Science Limited
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Employees
3,535
Date Price Change Volume
19/08/26 ₹957.00 +1.21% 18,163
18/08/26 ₹945.60 -4.20% 11,718
17/08/26 ₹987.05 +1.96% 32,335
14/08/26 ₹968.05 -1.75% 14,582
13/08/26 ₹985.30 -0.91% 14,471
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
957.50INR
Average target price
1,338.67INR
Spread / Average Target
+39.81%

Quarterly revenue - Rate of surprise